Navigation Links
ORTHOCON® Names David J. Hart Vice President of Business Operations
Date:3/15/2012

IRVINGTON, N.Y., March 15, 2012 /PRNewswire/ -- ORTHOCON®, Inc., a privately-held surgical device company, today announced that David J. Hart has been appointed Vice President of Business Operations. Mr. Hart will be responsible for in-licensing and acquiring new products and technologies for development and distribution by ORTHOCON's R&D and commercial teams. 

Mr. Hart joins ORTHOCON from Alpine Capital Group, a leading family office investment fund where, as President and Chief Investment Officer, he was responsible for all private equity and indirect capital investments and healthcare research. Prior to Alpine Capital, David was Principal and Senior Research Analyst at Apelles Investment Management, a cross-capital healthcare investment fund focused on public and private investing in medical device, healthcare service, and healthcare information technology companies. Mr. Hart began his career in the merger and acquisition groups at Thomas Weisel and Partners and Duff and Phelps. He earned a MBA from Columbia University and a BA from Duke where he was a member of the varsity golf team.

"I am thrilled to have David on our senior leadership team," said John J. Pacifico, President and Chief Executive Officer of ORTHOCON. "Having known David for several years and watched him achieve tremendous professional success directly relevant to ORTHOCON's business plan, I know he is perfect for this role and I fully expect him to add significant value to ORTHOCON and to our shareholders."

"I've had the opportunity to watch ORTHOCON evolve over the last five years. John has built a dynamic organization with a robust R&D pipeline and a truly differentiated commercialization strategy," said David Hart. "I am excited to join the ORTHOCON team and look forward to helping John execute on his strategic vision for the company."

About ORTHOCON
Founded in 2005, ORTHOCON develops, acquires, manufactures, and markets surgical products. In 2011, ORTHOCON announced the commercial introduction of its first FDA cleared product, Hemasorb Resorbable Hemostatic Bone Putty, and the clearance of Hemasorb Apply, a proprietary applicator designed to deliver Hemasorb and other ORTHOCON products presently under development. Also in 2011, ORTHOCON announced a strategic partnership with Bezwada Biomedical which gave ORTHOCON worldwide rights to develop and market Bezwada's absorbable polyurethane technology for bone applications. 

ORTHOCON is funded by leading international venture capital investment firms. The company occupies 8,000 square feet at its state-of-the-art facility in Irvington, New York. For more information, please visit www.orthocon.com.


'/>"/>
SOURCE ORTHOCON, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ORTHOCON®, Inc. Receives 510(k) Clearance to Market HEMASORB Apply™
2. ORTHOCON® Receives CE Mark and Health Canada Medical Device License for HEMASORB®
3. ORTHOCON® Announces U.S. Market Launch of HEMASORB®
4. Zeus Healthcare Names Larry Havelis as CEO
5. RoundTable Healthcare Partners Names Kent J. Davies CEO of Newly Formed Platform Development Corporation
6. InterMune Names Jonathan A. Leff, M.D., as Executive Vice President of Research and Development
7. SalesCongo Names Ken Kaisen CEO
8. UNT System Names Jacobson Founding Dean of College of Pharmacy
9. LoneStar Heart Inc. Names Andrew J. Coats, M.D., and Mark Maciejewski to Its Board of Directors
10. Premier Research Names Etienne Drouet Executive Director, Oncology Europe
11. Premier Research Names Susan Stansfield, PhD Executive VP, Clinical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... CLEMENTE, Calif. , June 24, 2016  American Respiratory Labs ... company, is now able to perform sophisticated lung assessments in patients, ... Technologies , Inc. Patients are no longer limited ... ndd,s EasyOne PRO ® , ARL patients like Jeanne R. of ... done in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing skills ... patients and their families pay tribute to a genetic counselor by nominating him or ... Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome magazine ...
Breaking Medicine News(10 mins):